This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View
by Zacks Equity Research
Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.
QIAGEN (QGEN) Wins FDA Clearance for NeuMoDx CT/NG Assay
by Zacks Equity Research
QIAGEN (QGEN) receives FDA clearance for the NeuMoDx CT/NG Assay for use on both NeuMoDx 96 and 288 versions of the integrated PCR-based clinical molecular testing system.
Glaukos' (GKOS) Preliminary Q4 Revenues Ride on Product Demand
by Zacks Equity Research
Glaukos' (GKOS) revenues in the fourth quarter have been primarily driven by the continued demand for existing and newly launched products.
Intuitive Surgical (ISRG) Preliminary Q4 Revenues Improve Y/Y
by Zacks Equity Research
Intuitive Surgical's (ISRG) fourth-quarter revenues reflect a strong demand in procedure volume as China recovers following the resurgence of COVID-19 in early 2023.
LabCorp (LH) to Expand Clinical Trails Access With New Pact
by Zacks Equity Research
LabCorp (LH) and Hawthorne Effect hope to enhance decentralized clinical trials by merging existing services and developing fresh, unique service offers.
Integer Holdings (ITGR) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Integer Holdings' (ITGR) revenue growth in the fourth quarter is likely to have been boosted by continued strong customer demand for its products.
The Zacks Analyst Blog Highlights DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics
by Zacks Equity Research
DaVita, monday.com, GitLab, Light & Wonder and Sarepta Therapeutics are part of the Zacks top Analyst Blog.
Medtronic's (MDT) Percept RC DBS System Secures FDA Approval
by Zacks Equity Research
Medtronic's (MDT) latest innovation joins the Percept family, the first and only DBS system with sensing, directionality and advanced programming.
Acadia Healthcare (ACHC) Inks JV to Better Serve Texas Residents
by Zacks Equity Research
Acadia Healthcare (ACHC) enters into a JV with Ascension Seton to expand the availability of inpatient behavioral beds across Austin and thereby, establish a solid footprint in the region.
Neogen's (NEOG) Q2 Earnings Miss Estimates, 2024 View Down
by Zacks Equity Research
Neogen's (NEOG) Q2 revenues decline year over year due to lower Animal Safety business.
Veradigm (MDRX) & MedAllies Partner for Better Care Decisions
by Zacks Equity Research
Veradigm's (MDRX) partnership with MedAllies is likely to gain access to a wider range of patient data and drive better treatment decisions.
Nevro's (NVRO) Preliminary Q4 Revenues Boosted by PDN Sales
by Zacks Equity Research
Nevro's (NVRO) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its PDN business.
Is Quest Diagnostics (DGX) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Cardinal Health (CAH) Streamlines Operation With New Structure
by Zacks Equity Research
Cardinal Health's (CAH) new reporting structure is likely to streamline operations, providing better visibility of growth areas. At-home solutions and OptiFreight Logistics are possibly the key value creators.
5 Mid-Cap Stocks to Buy in a Volatile January
by Nalak Das
We have narrowed our search to five mid-caps that have strong potential for 2024. These are: DVA, MNDY, GTLB, LNW, SRPT.
Here's Why Investors Should Retain Integra (IART) Stock Now
by Zacks Equity Research
Investors remain optimistic about Integra (IART) due to the positive outlook for its CSS segment.
Medtronic (MDT) Wins CE Mark for MiniMed 780G With Simplera Sync
by Zacks Equity Research
Medtronic (MDT) secures the CE Mark for the MiniMed 780G system with the disposable, all-in-one Simplera Sync CGM.
How to Find Great Momentum Stocks to Buy in 2024
by Benjamin Rains
The screen we explore today aims to find Zacks Rank #1 (Strong Buy) stocks that boast strong upward price momentum to help investors buy potential winners in January and throughout 2024.
Quest Diagnostics (DGX) to Boost Lab Services With New Buyout
by Zacks Equity Research
Quest Diagnostics' (DGX) recent acquisition seeks to increase accessibility to cutting-edge, high-caliber and reasonably priced laboratory services.
Here's Why You Should Retain Omnicell (OMCL) Stock Now
by Zacks Equity Research
Investors are optimistic about Omnicell (OMCL) owing to its strong Pharmacy model and geographical expansion.
QIAGEN (QGEN) Gains From New Alliances Amid FX Headwind
by Zacks Equity Research
QIAGEN (QGEN) is progressing well with its testing menu expansion strategy, which is driving the company's growth.
SenesTech's (SNES) New Partnership to Broaden Evolve's Scope
by Zacks Equity Research
The collaboration with a global leader in irrigation solutions for sustainable agriculture aligns with SenesTech's (SNES) target to introduce Evolve to a broader audience.
PacBio (PACB) Preliminary Q4 Revenues Boosted by Revio Sales
by Zacks Equity Research
PacBio's (PACB) revenue growth in the fourth quarter is likely to have been boosted by continued strength in its sequencing systems.
Inspire Medical (INSP) Reports Solid Preliminary Q4 Revenues
by Zacks Equity Research
Inspire Medical's (INSP) revenue growth in the fourth quarter is likely to have been boosted by improved operating leverage.
DexCom (DXCM) Preliminary Q4 Revenues Ride on Sensor Demand
by Zacks Equity Research
DexCom's (DXCM) revenue growth in the fourth quarter is likely to have been boosted by strong demand for its CGM sensors across the globe. It delivers robust revenue guidance for 2024.